Drimva

NewLimit

Scientist/Senior Scientist, Immunology

$130K–$180K

South San Francisco +1 · Senior · Full-time · Posted Feb 9, 2026

Location
South San Francisco
South San Francisco, California, United States
Experience
6+ years of relevant industry experience with a BS/MS, or Ph.D. (no years specified).
Education
Ph.D. in immunology, cell biology, or a related field, or BS/MS with 6+ years of relevant industry experience.

About the job

Leads immunology discovery-to-preclinical research for inflammatory and autoimmune diseases, focusing on T cell and Treg biology and epigenetic reprogramming interventions.

What you'll do

  • Develop scalable functional assays in T cells and Tregs to predict therapeutic activity and inform lead selection.
  • Design and lead in vivo and in vitro studies supporting target discovery, validation, and preclinical development.
  • Collaborate across teams to evaluate interventions and interpret multimodal datasets; contribute to study reports and regulatory-supporting documentation.

What they ask for

  • Ph.D. in immunology, cell biology, or a related field, or BS/MS with 6+ years of relevant industry experience.
  • Hands-on experience with multi-parameter flow cytometry.
  • Experience designing in vivo models of autoimmune or inflammatory disease.
  • Experience with primary immune cell isolation, ex vivo culture, and Treg functional assay.

Nice to have

  • Experience with pooled screening approaches, rheumatoid arthritis or colitis models, IND-supporting study reports, or CRO partnerships.
  • Familiarity with basic computational tools for data analysis, such as Python or R.

Pay

USD $130,000 to $180,000 base salary

Tools

multi-parameter flow cytometry, CRISPR fitness screens, Perturb-seq, CROP-seq, Python, R

AI focus

Collaborates with Predictive Modeling to evaluate epigenetic reprogramming interventions and integrate and interpret complex multimodal datasets.

Model-written summary · the original posting is authoritative

First seen Oct 29, 2026 · Last verified Nov 5, 2026 (UTC)